This study is testing two medicines, tiragolumab and atezolizumab, for treating tough-to-fight tumors in both kids and adults. These tumors are missing important genes, SMARCB1 or SMARCA4, and can be stubborn, either coming back or not responding to regular treatment. The medicines are a type of immunotherapy, which helps the immune system fight cancer, and might stop the tumors from growing and spreading.
- Participants receive treatments every 21 days, potentially for up to 5 years.
- Regular scans and blood tests are part of the study to monitor the treatment’s effects.
- Participants must be at least 12 months old, and part B is open to adults initially.
The study is divided into two parts: Part A focuses on younger patients under 18, and Part B includes adults and will later include younger patients once safety is confirmed. After treatment, follow-up visits continue for up to 5 years. Participants should not have had previous treatments that target similar immune pathways, and certain conditions like recent infections or severe allergies may prevent participation.